CN1448174A - Application of cymose buckwheat rhizome in preparation of antiviral drug - Google Patents
Application of cymose buckwheat rhizome in preparation of antiviral drug Download PDFInfo
- Publication number
- CN1448174A CN1448174A CN 03113355 CN03113355A CN1448174A CN 1448174 A CN1448174 A CN 1448174A CN 03113355 CN03113355 CN 03113355 CN 03113355 A CN03113355 A CN 03113355A CN 1448174 A CN1448174 A CN 1448174A
- Authority
- CN
- China
- Prior art keywords
- preparation
- application
- rhizoma fagopyri
- fagopyri dibotryis
- influenza virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is the application of golden buckwheat rhizome in the preparation of antiviral medicines. Golden buckwheat rhizome is used in preparing antiviral medicines, especially medicines for respiratory tract diseases caused by influenza virus, respiratory syncytial virus, etc. It has obvious pharmacological effect on the diseases caused by the said viruses.
Description
Technical field:
The present invention relates to a kind of medical usage of material, is the application of Rhizoma Fagopyri Dibotryis in pharmacy.
Background technology:
Rhizoma Fagopyri Dibotryis is as a kind of Chinese medicine, and its preparation is used to treat diseases such as emphysema, lung abscess traditionally, mainly has the function of evacuation of pus blood stasis dispelling.
Summary of the invention:
The object of the present invention is to provide the application of a kind of Rhizoma Fagopyri Dibotryis in the preparation antiviral drugs.
Technical solution of the present invention is:
The application of Rhizoma Fagopyri Dibotryis in the preparation antiviral drugs.
Described antiviral drugs is the medicine of treatment respiratory viral disease.
Described antiviral drugs is the medicine of treatment influenza virus property disease.
Described antiviral drugs is the medicine of treatment respiratory syncytial virus disease.
The present invention is used to prepare antiviral drugs with Rhizoma Fagopyri Dibotryis, treats the medicine of the respiratory tract disease of infection such as influenza virus, respiratory syncytial virus especially for preparation, and the disease that causes for the above-mentioned virus of treatment has tangible pharmacological action.
The specific embodiment:
Embodiment 1:
Depletion Semen Fagopyri Esculenti medical material is selected, and removes impurity, cleans, and dries, and (major diameter 2～20mm, minor axis 1～10mm) add 1-10 and doubly measure the 20-90% alcohol reflux three times, each 0.5-3.0 hour to be broken into coarse granule.Extracting solution concentrates (steam pressure: 0.005～0.06MP with No. seven sievings, filtrate decompression
aTemperature: 45～85 ℃; Vacuum: 0.03～0.08MP
a) become the concentrated solution of relative density 1.05～1.25 (40～60 ℃), add antioxidant and intercalating agent, mixing.Concentrated solution spray drying (100～180 ℃ of intake air temperatures, 55～100 ℃ of air outlet temperature) is made extract powder, adds excipient, and mixing is granulated, and adds magnesium stearate, mixing, filled capsules.
Antioxidant can be vitamin C, sodium sulfite, sodium thiosulfate, cysteine etc., and its consumption is 0.001%～0.004% of a Rhizoma Fagopyri Dibotryis weight; Intercalating agent can be tartaric acid, two mercapto ethyl glycines, edetate, citric acid etc., and its consumption is 0.001%～0.006% of a Rhizoma Fagopyri Dibotryis weight; Excipient is conventional excipients (can be ethyl cellulose, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium or low-substituted hydroxypropyl cellulose).
The capsule that obtains is used for the treatment of influenza virus property disease and treatment respiratory syncytial virus disease.
Embodiment 2:
Commercially available Rhizoma Fagopyri Dibotryis preparation (Nantong Jinghua Pharmacy Co. Ltd's production) is used for the treatment of influenza virus property disease and treatment respiratory syncytial virus disease.
Rhizoma Fagopyri Dibotryis preparation with embodiment 1 is the checking medicine; With the positive control drug of ribavirin injection (Suzhou No.6 Pharmaceutical Factory produces, lot number 000223), following determination test result is arranged:
Table 1 Rhizoma Fagopyri Dibotryis is to the toxicity test result of mdck cell and VERO cell
| Medicine | Test method | Mdck cell | The VERO cell | ||
| ?TD 0μg/ml | TD 50μg/ml | TD 0μg/ml | ?TD 50μg/ml | ||
| Rhizoma Fagopyri Dibotryis | The CPE method | ?625±0 | 1250±0 | 625±0 | ?1212±66 |
| Mtt assay | ?979.6±35.2 | 1502±66.5 | 662±64 | ?1250±0 | |
| Ribavirin | The CPE method | ?＞1000±0 | ＞1000±0 | ＞1000±0 | ?＞1000±0 |
| Mtt assay | ?＞1000±0 | ＞1000±0 | ＞1000±0 | ?＞1000±0 | |
Table 2 Rhizoma Fagopyri Dibotryis influenza first 3 type viruses, anti-RSV virus result of the test
| Medicine | Test method | Influenza first 3 type viruses | Anti-RSV virus | ||||
| IC 50g/ml | MICμg/ml | TI | IC 50μg/ml | MICμg/ml | TI | ||
| Rhizoma Fagopyri Dibotryis | The CPE method | 10±0.5 | 18.3±2.0 | 34.4 | 13±5.6 | 39±0 | 16 |
| Mtt assay | 10±0.4 | 18.3±2.0 | 34.4 | 16.3±5.6 | 39±0 | 16 | |
| Ribavirin | The CPE method | ＜7.8±0 | ＜7.8±0 | 128 | ＜7.8±0 | ＜7.8±0 | 128 |
| Mtt assay | ＜7.8±0 | ＜7.8±0 | 128 | ＜7.8±0 | ＜7.8±0 | 128 | |
The resisiting influenza virus test of pesticide effectiveness is the result of the test of indication with mouse death rate, protective rate in the table 3 Rhizoma Fagopyri Dibotryis body
| Medicine name | Drug dose (g/Kg) | Number of mice (only) | The survival number | Death toll | Mortality rate % | Protective rate % | Statistical procedures | Interpretation of result | |
| ?????X 2 | ??????P | Obvious resisiting influenza virus effect is arranged | |||||||
| Rhizoma Fagopyri Dibotryis | ?????5 | ???30 | ????30 | ????0 | ????0 | ????100 | ????49.1 | ??＜0.01 | Obvious resisiting influenza virus effect is arranged |
| ????2.5 | ???30 | ????23 | ????7 | ????23 | ????74 | ????27.2 | ??＜0.01 | Obvious resisiting influenza virus effect is arranged | |
| ????1.25 | ???30 | ????18 | ????12 | ????40 | ????56 | ????16.5 | ??＜0.01 | Obvious resisiting influenza virus effect is arranged | |
| Ribavirin | ????0.1 | ???30 | ????30 | ????0 | ????0 | ????100 | ????49.1 | ??＜0.01 | Obvious resisiting influenza virus effect is arranged |
| ????0.05 | ???30 | ????29 | ????1 | ????3 | ????97 | ????45.3 | ??＜0.01 | Obvious resisiting influenza virus effect is arranged | |
| ????0.025 | ???30 | ????29 | ????1 | ????3 | ????97 | ????45.3 | ??＜D.01 | Obvious resisiting influenza virus effect is arranged | |
| Virus control | ??10?LD 50 | ???30 | ?????3 | ????27 | ????90 | ||||
The resisiting influenza virus test of pesticide effectiveness is the result of the test of indication with the mouse lung pathological changes in the table 4 Rhizoma Fagopyri Dibotryis body
| Medicine name | Drug dose (g/Kg) | Number of mice (only) | Pulmonary lesion | Pulmonary lesion rate % | Pulmonary lesion slip % | Statistical procedures | Interpretation of result | ||
| Have | Do not have | ????X 2 | ????P | Obvious resisiting influenza virus effect is arranged | |||||
| Rhizoma Fagopyri Dibotryis | ?????5 | ???30 | ????2 | ????28 | ????7 | ????91 | ???30.2 | ??＜0.01 | Obvious resisiting influenza virus effect is arranged |
| ?????2.5 | ???30 | ????5 | ????25 | ????17 | ????78 | ???21.7 | ??＜0.01 | Obvious resisiting influenza virus effect is arranged | |
| ?????1.25 | ???30 | ????11 | ????19 | ????37 | ????52 | ????9.8 | ??＜0.01 | Obvious resisiting influenza virus effect is arranged | |
| Ribavirin | ?????0.1 | ???30 | ????0 | ????30 | ????0 | ????100 | ???37.3 | ??＜0.01 | Obvious resisiting influenza virus effect is arranged |
| ?????0.05 | ???30 | ????3 | ????27 | ????10 | ????87 | ???27.2 | ??＜0.01 | Obvious resisiting influenza virus effect is arranged | |
| ?????0.025 | ???30 | ????4 | ????26 | ????13 | ????83 | ???24.3 | ??＜0.01 | Obvious resisiting influenza virus effect is arranged | |
| Virus control | ??10?LD 50 | ???30 | ????23 | ????7 | ????77 | ||||
Claims (4)
1, the application of Rhizoma Fagopyri Dibotryis in the preparation antiviral drugs.
2, the application of Rhizoma Fagopyri Dibotryis according to claim 1 in the preparation antiviral drugs is characterized in that: described antiviral drugs is the medicine of treatment respiratory viral disease.
3, the application of Rhizoma Fagopyri Dibotryis according to claim 1 and 2 in the preparation antiviral drugs is characterized in that: described antiviral drugs is the medicine of treatment influenza virus property disease.
4, the application of Rhizoma Fagopyri Dibotryis according to claim 1 and 2 in the preparation antiviral drugs is characterized in that: described antiviral drugs is the medicine of treatment respiratory syncytial virus disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB03113355XA CN1181883C (en) | 2003-05-03 | 2003-05-03 | Application of cymose buckwheat rhizome in preparation of antiviral drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB03113355XA CN1181883C (en) | 2003-05-03 | 2003-05-03 | Application of cymose buckwheat rhizome in preparation of antiviral drug |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410055564 Division CN1244330C (en) | 2003-05-03 | 2003-05-03 | Application of golden buckwheat rhizome in the preparing process of medicine for treating respiratory syncytial virus infected disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1448174A true CN1448174A (en) | 2003-10-15 |
| CN1181883C CN1181883C (en) | 2004-12-29 |
Family
ID=28684041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB03113355XA Expired - Lifetime CN1181883C (en) | 2003-05-03 | 2003-05-03 | Application of cymose buckwheat rhizome in preparation of antiviral drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1181883C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100455304C (en) * | 2004-06-25 | 2009-01-28 | 曲靖开发区格力康生物科技发展有限公司 | Compound Jinqiaomai preparation |
| CN103989754A (en) * | 2014-06-03 | 2014-08-20 | 精华制药集团股份有限公司 | Application of wild buckwheat in preparation of medicine for reducing PM2.5 damage to human body |
| CN107233392A (en) * | 2017-06-20 | 2017-10-10 | 佳木斯诺亚医药科技有限公司 | Gold dripping pill and preparation method thereof |
-
2003
- 2003-05-03 CN CNB03113355XA patent/CN1181883C/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100455304C (en) * | 2004-06-25 | 2009-01-28 | 曲靖开发区格力康生物科技发展有限公司 | Compound Jinqiaomai preparation |
| CN103989754A (en) * | 2014-06-03 | 2014-08-20 | 精华制药集团股份有限公司 | Application of wild buckwheat in preparation of medicine for reducing PM2.5 damage to human body |
| CN107233392A (en) * | 2017-06-20 | 2017-10-10 | 佳木斯诺亚医药科技有限公司 | Gold dripping pill and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1181883C (en) | 2004-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1194752C (en) | Anti-virus Chinese medicine composition and preparation process thereof | |
| KR101566441B1 (en) | Composition for prevention and treatment of influenza virus and composition for inhibiting the activity of neuraminidase comprising extracts of Turmeric | |
| CN108578421B (en) | Application of phillyrin/phillygenin composition in preparation of medicines for relieving or/and treating viral diseases | |
| CN102000156A (en) | Traditional Chinese medicine compound preparation for treating cold, influenza and upper respiratory tract infection | |
| WO2021179950A1 (en) | Use of pharmaceutical composition in preparing anti-viral drug | |
| Mazraedoost et al. | Covid-19 treatment by plant compounds | |
| CN101683420B (en) | Applications of traditional Chinese medicine composition in preparation of medicament for treating acute pharyngitis | |
| CN101991694A (en) | Application of traditional Chinese medical composition in preparation of medicament for resisting influenza A H1N1 influenza viruses | |
| Chauhan et al. | Natural products as environmentally safe and green approach to combat Covid-19 | |
| CN1181883C (en) | Application of cymose buckwheat rhizome in preparation of antiviral drug | |
| Fasogbon et al. | Positive therapeutic role of selected foods and plant on ailments with a trend towards COVID-19: a review | |
| CN1803179B (en) | Traditional Chinese medicine composition and its preparation method and quality control method | |
| CN100556415C (en) | The medicine of a kind of influenza and bird flu virus | |
| CN1244330C (en) | Application of golden buckwheat rhizome in the preparing process of medicine for treating respiratory syncytial virus infected disease | |
| CN102836168B (en) | Application of indole-3-acetonitrile-6-O-beta-D-pyran glucoside in pharmacy | |
| WO2015109900A1 (en) | Use of saikosaponin a in prepaing medicaments for preventing and treating influenza in humans and animals | |
| CN105616921A (en) | Traditional Chinese medicine composition for treating upper respiratory tract infection and preparation method thereof | |
| CN112138133B (en) | Pharmaceutical composition for treating novel coronavirus pneumonia and preparation method and application thereof | |
| CN103933002A (en) | Scutellaria baicalensis total flavonoid sustained release tablet and preparation method thereof | |
| CN113116867B (en) | Composition for preventing and/or treating influenza | |
| CN109700899B (en) | Sichuan blackberry lily scutellaria baicalensis flavone extract and preparation method and application thereof | |
| CN101816706B (en) | Chinese traditional medicament valid target composition for treating viral respiratory infection diseases | |
| CN103735599B (en) | Herba laggera extract and application in anti-Alphavirus flu pharmaceutical for the composition | |
| CN100448450C (en) | Pharyngolaryngitis-treating pharmaceutical compositions and its preparing method | |
| CN110302166A (en) | A kind of swap buffers tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: NANTONG ESSENCE PHARMACEUTICAL CO. Free format text: FORMER NAME OR ADDRESS: NANTONG JINGHUA PHARMACY CO. LTD. |
|
| CP03 | Change of name, title or address |
Address after: Jiangsu city of Nantong province Gangzha Xingtai Road Economic Development Zone No. 9 Patentee after: NANTONG JINGHUA PHARMACEUTICAL Co.,Ltd. Address before: Jiangsu city of Nantong province Gangzha Xingtai Road Economic Development Zone No. 9 Patentee before: Nantong Jinghua Pharmacy Co.,Ltd. |
|
| C56 | Change in the name or address of the patentee |
Owner name: JINGHUA PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: NANTONG JINGHUA PHARMACY CO. LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 226005 Jiangsu city of Nantong province Gangzha Xingtai Road Economic Development Zone No. 9 Patentee after: JINGHUA PHARMACEUTICAL GROUP Co.,Ltd. Address before: 226005 Jiangsu city of Nantong province Gangzha Xingtai Road Economic Development Zone No. 9 Patentee before: NANTONG JINGHUA PHARMACEUTICAL Co.,Ltd. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20041229 |